The Role of Tet2-Mutant Clonal Hematopoiesis in BRAF-V600E-Driven Anaplastic Thyroid Cancer


2024 Momentum Fellow

Vera Tiedje, MD, PhD, Memorial Sloan Kettering Cancer Center

Vera Tiedje, MD, PhD

Thyroid cancers are the most common tumor associated with clonal hematopoiesis (CH), and CH is associated with worse outcomes in other solid tumor patients, although the specific consequences of CH on therapy response are unknown. Dr. Tiedje has developed a mouse model of concurrent CH and thyroid cancer to study the impact of CH on thyroid tumor biology and therapy response.

published research

Tiedje V, Greenberg J, Qin T, Im SY, Krishnamoorthy GP, Boucai L, Xu B, French JD, Sherman EJ, Ho AL, de Stanchina E, Socci ND, Jin J, Ghossein RA, Knauf JA, Koche RP, Fagin JA. Loss of tumor cell MHC Class II drives MAPK-inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers. J Clin Invest. 2025.

BACK TO OUR PORTFOLIO